A number of investment brokers have recently updated their price targets on shares of AbbVie Inc. (NYSE:ABBV). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/25/2016 – AbbVie Inc. had its “overweight” rating reiterated by analysts at Credit Suisse.

04/06/2016 – Societe Generale began new coverage on AbbVie Inc. giving the company a “sell” rating. They now have a USD 47 price target on the stock.

03/15/2016 – Deutsche Bank began new coverage on AbbVie Inc. giving the company a “hold” rating. They now have a USD 63 price target on the stock.

03/07/2016 – AbbVie Inc. was downgraded to “buy” by analysts at Goldman Sachs. They now have a USD 68 price target on the stock.

02/23/2016 – AbbVie Inc. was upgraded to “buy” by analysts at Citigroup. They now have a USD 65 price target on the stock.

02/22/2016 – AbbVie Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 80 price target on the stock.

02/05/2016 – William Blair began new coverage on AbbVie Inc. giving the company a “outperform” rating. They now have a USD 76 price target on the stock.

01/27/2016 – AbbVie Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 70 price target on the stock.

12/18/2015 – Atlantic Equities began new coverage on AbbVie Inc. giving the company a “neutral” rating.

12/03/2015 – AbbVie Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 70 price target on the stock.

12/01/2015 – AbbVie Inc. was downgraded to “equal weight” by analysts at Barclays. They now have a USD 72 price target on the stock.

11/02/2015 – AbbVie Inc. was upgraded to “overweight” by analysts at Morgan Stanley. They now have a USD 73 price target on the stock.

11/02/2015 – AbbVie Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 78 price target on the stock.

10/23/2015 – AbbVie Inc. had its “buy” rating reiterated by analysts at JP Morgan.

07/23/2015 – AbbVie Inc. had its “buy” rating reiterated by analysts at Evercore ISI. They now have a USD 70 price target on the stock.

The share price of AbbVie Inc. (NYSE:ABBV) was up +0.27% during the last day of trading, with a day high of 62.74. 10880707 shares were traded during the last session.

The stock’s 50 day moving average is 59.33 and its 200 day moving average is 57.47. The stock’s market capitalization is 100.72B. AbbVie Inc. has a 52-week low of 45.45 and a 52-week high of 71.60.

View other investors thoughts on AbbVie Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.